Research aims to personalize AMD therapies

By: Joan W. Miller
VANCOUVER, British Columbia — Much like the development of anti-VEGF was transformational in the treatment of age-related macular degeneration, the future identification of key pathways, potential therapeutic targets in those pathways and a better understanding of the disease could have a similar effect on treatment, Joan W. Miller, MD, said in the Pyron Award lecture at the American Society of Retina Specialists annual meeting.
Miller discussed the need for developing new therapies for early and intermediate age-related macular degeneration (AMD).

“In order to develop the next generation of therapies for AMD, but in the early and intermediate stages, we need to think about the key pathways and the targets there, and then improve our understanding of structure/function, genotype/phenotype relation, develop systemic biomarkers, perhaps leading to the reclassification and delineation of subtypes in early and intermediate AMD. Ultimately, we would like to develop personalized medicine for patients,” Miller said.
By identifying systemic biomarkers for AMD, such as in plasma or urine, ophthalmologists could potentially identify patients with AMD, correlate with disease progression, and provide personalized treatments, she said. – by Robert Linnehanid….
Source: Healio